Hedberg Pontus, van der Werff Suzanne Desirée, Nauclér Pontus
Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
J Infect Dis. 2025 Jun 2;231(5):e941-e944. doi: 10.1093/infdis/jiaf133.
We conducted a population-based cohort study in Stockholm, Sweden, to investigate the effect of COVID-19 vaccination on the risk of developing persistent post-COVID-19 condition (PCC) in individuals surviving the first year after a SARS-CoV-2 infection. In total, 331 042 individuals were included, of which 852 had persistent PCC. The adjusted risk ratio for developing persistent PCC compared with unvaccinated individuals was 0.81 (95% confidence interval [CI], .59-1.10) for 1 dose, 0.42 (95% CI, .35-.52) for 2 doses, and 0.37 (95% CI, .27-.52) for 3 doses. Reduced risks for vaccinated individuals were also observed when restricting the analyses to pre-Omicron and Omicron, as well as all subgroups including sex, age, and previous infection.
我们在瑞典斯德哥尔摩开展了一项基于人群的队列研究，以调查新冠病毒疫苗接种对感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）后存活一年的个体发生新冠后持续症状（PCC）风险的影响。总共纳入了331042名个体，其中852人患有持续性PCC。与未接种疫苗的个体相比，接种1剂疫苗后发生持续性PCC的调整风险比为0.81（95%置信区间[CI]，0.59 - 1.10），接种2剂为0.42（95%CI，0.35 - 0.52），接种3剂为0.37（95%CI，0.27 - 0.52）。在将分析限制在奥密克戎毒株出现之前和奥密克戎毒株流行期间，以及包括性别、年龄和既往感染情况在内的所有亚组中，也观察到接种疫苗个体的风险降低。
Zotero 插件